T 세포 매개형 약물과민반응: Stevens Johnson 증후군 및 독성 표피 괴사융해증(Toxic Epidermal Necrolysis)

참고문헌 (60)

1. Rawlins M, "Mechanisms of adverse drug reactions. in: Textbook of adverse drug reactions", pp.18~45 (1991), Oxford University Press
2. Lazarou J, "Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies", JAMA, 279, pp.1200~1205 (1998)
3. Svensson CK, "Cutaneous drug reactions", Pharmacological Reviews, 53, pp.357~379 (2001)
4. Pichler WJ, "Delayed drug hypersensitivity reactions", Ann Int Med, 139, pp.683~693 (2003)
5. Stevens AM, "A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children", Am L Dis Child, 24, pp.526~533 (1922)
6. Lyell A, "Toxic epidermal necrolysis: an eruption resembling scalding of the skin", Br J Dermatol, 68, pp.355~361 (1956)
7. Landsteiner K, "Studies on the sensitisation of animals with simple chemical compounds", J Exp Med, 61, pp.643~656 (1953)
8. Park BK, "Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective", Chem Res Toxicol, 11, pp.969~987 (1998)
9. Naisbitt DJ, "Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment", Drug Saf, 23, pp.483~507 (2000)
10. Padovan E, "Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy", Eur J Immunol, 27, pp.1303~1307 (1997)
11. Lavergne SN, "The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity", Curr Opin Allergy Clin Immunol, 8, pp.299~307 (2008)
12. Knowles SR, "Idiosyncratic drug reactions: the reactive metabolite syndromes", Lancet, 356, pp.1587~1591 (2000)
13. Griem P, "Allergic and autoimmune reactions to xenobiotics: how do they arise?", Immunol Today, 19, pp.133~141a (1998)
14. Pichler WJ, "Pharmacological interaction of drugs with immune receptors: the p-i concept", Allergol Int, 55, pp.17~25 (2006)
15. Schnyder B, "Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+T cells from allergic individuals", J Immunol, 164, pp.6647~6654 (2000)
16. Burkhart C, "Influence of reduced glutathione on the proliferative response of sulfamethoxazole- specific and sulfamethoxazole-metabolite-specific human CD4+T cells", Br J Pharmacol, 132, pp.623~630 (2001)
17. Coombs PR, "Classification of allergic reactions responsible for clinical hypersensitivity and disease. in: inical aspects of immunology", pp.575~596 (1968), Oxford University Press
18. Pichler WJ, "Delayed drug hypersensitivity reactions - new concepts", Clinical & Experimental Allergy, 37, pp.989~999 (2007)
19. Nassif A, "Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis", J Invest Dermatol, 118, pp.728~733 (2002)
20. Yawalkar N, "cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic", J Invest Dermatol, 115, pp.647~652 (2000)
21. Schnyder B, "T-cell mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction", Clin Exp Allergy, 28, pp.1412~1417 (1998)
22. Mauri-Hellweg D, "Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfamethoxazole, phenytoin and carbamazepine", J Immunol, 155, pp.462~472 (1995)
23. )Hashizume H, "Characterization of drug- specific T-cells in Phenobarbital-induced eruption", J Immunol, 168, pp.5359~5368 (2002)
24. Cleach L, "Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors", Clin Exp Immunol, 119, pp.225~230 (2000)
25. Rotunda A, "Severe cutaneous reactions associated with the use of human immunodeficiency virus medications", Acta Derm Venereol, 83, pp.1~9 (2003)
26. Borrás-Blasco J, "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection", J Antimicrob Chemother, 62, pp.879~888 (2008)
27. Paquet P, "Factor-XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes", Dermatology, 206, pp.374~378 (2003)
28. Paquet P, "Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns", Int J Mol Med, 1, pp.459~462 (1998)
29. Roujeau JC, "Immune mechanisms in drug allergy", Allergol Int, 55, pp.27~33 (2006)
30. Mizukawa Y, "Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption", Am J Pathol, 161, pp.1337~1347 (2002)
31. Hari Y, "T cell involvement in cutaneous drug eruptions", Clin Exp Allergy, 31, pp.1398~1408 (2001)
32. Correia O, "Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis", J Am Acad Dermatol, 47, pp.58~62 (2002)
33. Nassif A, "Evaluation of the potential role of cytokines in toxic epidermal necrolysis", J Invest Dermatol, 123, pp.850~855 (2004)
34. Caproni M, "Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens- Johnson syndrome", toxic epidermal necrolysis, 2006, pp.155, 722~728
35. Hunger RE, "Rapid resolution of toxic epidermal necrolysis with anti- TNF-alpha treatment", J Allergy Clin Immunol, 117, pp.S464~S470 (2006)
36. Teraki Y, "IFN-gamma-producing effector CD8 cells and IL-10 producing regulatory CD4+ T cells in fixed drug eruptions", J Allergy Clin Immunol, 112, pp.609~615 (2003)
37. Azukizawa H, "Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes", Eur J Immunol, 33, pp.1879~1888 (2003)
38. Azukizawa H, "Prevention of toxic epidermal necrolysis by regulatory T cells", Eur J Immunol, 35, pp.1722~1733 (2005)
39. Pirmohamed M, "Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis", Pharmacogenomics, 8, pp.1661~1691 (2007)
40. Lonjou C, "A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. RegiSCAR study group", Pharmacogenet Genomics, 18, pp.99~107 (2008)
41. Horton R, "Gene map of the extended human MHC", Nat Rev Genet, 512, pp.889~899 (2004)
42. Martin AM, "Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant", Proc Natl Acad Sci U S A, 통권 : 23, pp.4180~4185 (2004)
43. Hung SI, "Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions", Pharmacogenet Genomics, 16, pp.297~306 (2006)
44. Chung WH, "Human leukocyte antigens and drug hypersensitivity", Curr Opin Allergy Clin Immunol, 7, pp.317~323 (2007)
45. Lonjou C, "RegiSCAR study group A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs", Pharmacogenet Genomics, 18, pp.99~107 (2008)
46. Lonjou C, "A marker for Stevens-Johnson syndrome: ethnicity matters; RegiSCAR Group", Pharmacogenomics J, 6, pp.265~268 (2006)
47. Hung SI, "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol", Proc Natl Acad Sci U S A, 통권 : 102, pp.4134~4139 (2005)
48. Paul C, "Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis", Br J Dermatol, 134, pp.710~714 (1996)
49. Becker DS, "Toxic epidermal necrolysis", Lancet, 351, pp.1417~1420 (1998)
50. Viard I, "Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin", Science, 282, pp.490~493 (1998)
51. Lerner LH, "Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome", J Invest Dermatol, 114, pp.196~199 (2000)
52. Shi Y, "Mechanisms of caspase activation and inhibition during apoptosis", Mol Cell, 9, pp.459~470 (2002)
53. Viard-Leveugle I, "Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions", J Biol Chem, 278, pp.16183~16188 (2003)
54. French LE, "Protein-based therapeutic approaches targeting death receptors", Cell Death Differ, 10, pp.117~123 (2003)
55. Abe R, "Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand", Am J Pathol, 162, pp.1515~1520 (2003)
56. Posadas SJ, "Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity", J Allergy Clin Immunol, 109, pp.155~161 (2002)
57. Teo L, "Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options", Singapore Med J, 50, pp.29~33 (2009)
58. Araki Y, "Successful treatment of stevens-johnson syndrome with steroid pulse therapy at disease onset", Am J Ophthalmol, 13 (2009)
59. Mittmann N, "Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome", Am J Clin Dermatol, 7, pp.359~368 (2006)
60. Arévalo JM, "Treatment of toxic epidermal necrolysis with cyclosporin", A Trauma, 48, pp.473~478 (2000)

관련 논문AI추천